Encompass Health Corp (EHC) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Encompass Health Corporation is the nation's largest owner and operator of inpatient rehabilitation hospitals, operating 163 facilities across 37 states and Puerto Rico. The company operates 99 wholly-owned hospitals and retains 50.0% to 97.5% ownership in 64 jointly owned hospitals. The filing is a Form 10-Q for a large accelerated filer.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Net Operating Revenues | $1,301.2 million | $1,187.1 million | $2,617.2 million | $2,347.5 million |
| Net Income (Consolidated) | $146.5 million | $117.2 million | $285.3 million | $230.5 million |
| Net Income Attributable to Encompass Health | $114.1 million | $91.4 million | $226.6 million | $179.1 million |
| Diluted EPS (Attributable to EHC) | $1.12 | $0.90 | $2.22 | $1.77 |
| Operating Cash Flow (YTD) | $456.2 million (2024) vs $434.6 million (2023) | |||
| Adjusted EBITDA (YTD) | $544.8 million (2024) vs $478.6 million (2023) | |||
| Total Debt (Long-term + Current) | $2,716.6 million (as of June 30, 2024) | |||
| Cash and Cash Equivalents | $154.4 million (as of June 30, 2024) |
Margins: Operating expenses as a percentage of net operating revenues were 83.4% for Q2 2024 and 83.8% for the six months ended June 30, 2024, compared to 84.5% and 84.6% in the prior year periods, respectively.
Material Changes vs. Prior Period
- Revenue Growth: Net operating revenues increased 9.6% in Q2 and 11.5% YTD compared to 2023, driven primarily by volume growth. Same-store discharges increased 4.8% in Q2 and 5.5% YTD.
- Profitability: Net income attributable to Encompass Health increased 24.8% in Q2 and 26.5% YTD. Pre-tax income from continuing operations rose 23.0% in Q2.
- Expense Trends: Salaries and benefits increased 10.1% in Q2 due to cost increases and higher volumes. General and administrative expenses decreased 8.8% in Q2 due to higher volumes and lower incentive compensation.
- Impairment Charge: The company incurred a one-time impairment charge of $10.4 million in Q1 2024 related to the closure of a joint venture hospital in Eau Claire, Wisconsin. This reduced YTD net income attributable to Encompass Health by approximately $1.8 million after tax and noncontrolling interest adjustments.
- Capital Expenditures: Capital spending increased to $296.3 million YTD 2024 from $221.7 million YTD 2023, reflecting new hospital openings and capacity expansions.
Guidance, Outlook, and Risks
- Dividend Increase: On July 24, 2024, the Board increased the quarterly cash dividend to $0.17 per share (from $0.15), payable October 15, 2024.
- Share Repurchases: The Board reset the aggregate common stock repurchase authorization to $500 million on July 24, 2024. The company repurchased 0.2 million shares for $16.8 million during the first six months of 2024.
- Debt Redemption: The company issued notice to redeem $150 million of its 5.75% Senior Notes due 2025 on August 15, 2024, using cash on hand. An approximate $0.4 million loss on early extinguishment is expected in Q3 2024.
- Regulatory Environment: The CMS 2025 Final Rule for Inpatient Rehabilitation Facilities (IRFs) is expected to result in a net increase to Medicare payment rates of approximately 3.3% effective October 1, 2024. The company is subject to the Review Choice Demonstration (RCD) in Alabama, Pennsylvania, and potentially Texas and California, which involves 100% pre-claim review for certain hospitals.
- Expansion: The company opened new facilities in Kissimmee, FL; Atlanta, GA; and Louisville, KY in 2024, and added 115 beds to existing hospitals. Several de novo projects are scheduled for 2024-2026.
- Risks: Key risks include changes in Medicare reimbursement, regulatory compliance (including False Claims Act/qui tam suits), staffing shortages, and the financial health of joint venture partners.
Investor Verification Checklist
- Debt Maturity Profile: Verify the impact of the $150 million 2025 Notes redemption on liquidity and the remaining debt schedule, noting no significant maturities in 2024.
- Regulatory Impact: Monitor the implementation of the CMS 2025 Final Rule and the expansion of the Review Choice Demonstration (RCD) to Texas and California, which could affect claim collectability and cash flow timing.
- Joint Venture Performance: Review the financial contribution of joint ventures, which represent a significant portion of the portfolio, and the impact of the recent Augusta, GA joint venture expansion.
- Capital Allocation: Track the execution of the new $500 million share repurchase authorization and the sustainability of the increased dividend against cash flow generation.
- Impairment and One-Time Items: Assess the frequency of impairment charges related to joint venture closures or regulatory changes, as seen with the Eau Claire, WI facility.